SELLAS Life Sciences Group, Inc. (SLS) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
7 TIMES SQUARE NEW YORK, NY 10036 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 13,886 | 2,530 | 17,125 | 21,355 | 35,302 | 7,277 | |||
| Cash and cash equivalent | 13,886 | 2,530 | 17,125 | 21,355 | 35,302 | 7,277 | |||
| Restricted cash and investments | 100 | 100 | 100 | 100 | 100 | 100 | |||
| Prepaid expense | 39 | 87 | 265 | 244 | 251 | 284 | |||
| Capitalized contract cost | 1,128 | ||||||||
| Other undisclosed current assets | 2,302 | 455 | 266 | 1,345 | 144 | 581 | |||
| Total current assets: | 16,327 | 3,172 | 17,756 | 23,044 | 36,925 | 8,242 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 925 | 858 | 874 | 723 | 896 | 217 | |||
| Intangible assets, net (including goodwill) | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 | |||
| Goodwill | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 | |||
| Deposits noncurrent assets | 266 | 275 | 399 | 594 | 614 | 536 | |||
| Other undisclosed noncurrent assets | 5,700 | 5,700 | |||||||
| Total noncurrent assets: | 3,105 | 3,047 | 3,187 | 3,231 | 9,124 | 8,367 | |||
| TOTAL ASSETS: | 19,432 | 6,219 | 20,943 | 26,275 | 46,049 | 16,609 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 8,966 | 13,289 | 9,643 | 4,784 | 6,570 | 5,073 | |||
| Accounts payable | 3,500 | 5,639 | 3,357 | 2,144 | 4,657 | 3,902 | |||
| Accrued liabilities | 5,466 | 7,650 | 6,286 | 2,640 | 1,913 | 1,171 | |||
| Deferred revenue | 5,600 | ||||||||
| Debt | 217 | ||||||||
| Other undisclosed current liabilities | 544 | 446 | 5,872 | 198 | 166 | ||||
| Total current liabilities: | 9,510 | 13,735 | 15,515 | 4,982 | 12,336 | 5,290 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 610 | 825 | |||||||
| Liabilities, other than long-term debt | 457 | 460 | 573 | 239 | 262 | ||||
| Deferred income tax liabilities | 239 | 262 | |||||||
| Operating lease, liability | 457 | 460 | 573 | 610 | 825 | ||||
| Other undisclosed noncurrent liabilities | 4 | (274) | 4,688 | 4,964 | |||||
| Total noncurrent liabilities: | 457 | 460 | 577 | 946 | 5,752 | 5,226 | |||
| Total liabilities: | 9,967 | 14,195 | 16,092 | 5,928 | 18,088 | 10,516 | |||
| Equity | |||||||||
| Equity, attributable to parent | 9,465 | (7,976) | 4,851 | 20,347 | 27,961 | 6,093 | |||
| Common stock | 7 | 3 | 2 | 2 | 1 | 5 | |||
| Additional paid in capital | 257,583 | 209,265 | 184,753 | 158,948 | 145,864 | 107,235 | |||
| Accumulated deficit | (248,125) | (217,244) | (179,904) | (138,603) | (117,904) | (101,147) | |||
| Total equity: | 9,465 | (7,976) | 4,851 | 20,347 | 27,961 | 6,093 | |||
| TOTAL LIABILITIES AND EQUITY: | 19,432 | 6,219 | 20,943 | 26,275 | 46,049 | 16,609 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,000 | 7,600 | 1,900 | |||||
| Cost of revenue | (100) | (200) | (20,041) | |||||
| Cost of product and service sold | (100) | (200) | ||||||
| Gross profit: | 900 | 7,400 | 1,900 | (20,041) | ||||
| Operating expenses | (31,513) | (37,869) | (42,850) | (32,694) | (18,882) | |||
| Operating loss: | (31,513) | (37,869) | (41,950) | (25,294) | (16,982) | (20,041) | ||
| Nonoperating income (expense) | 632 | 529 | 649 | 4,358 | 208 | (19,373) | ||
| Other nonoperating income | 208 | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (30,881) | (37,340) | (41,301) | (20,936) | (16,774) | (39,414) | ||
| Other undisclosed income from continuing operations before income taxes | 20,042 | |||||||
| Loss from continuing operations before income taxes: | (30,881) | (37,340) | (41,301) | (20,936) | (16,774) | (19,372) | ||
| Income tax benefit | 237 | 17 | 81 | |||||
| Other undisclosed loss from continuing operations | (1) | |||||||
| Loss from continuing operations: | (30,881) | (37,340) | (41,301) | (20,699) | (16,757) | (19,292) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (20,699) | (16,757) | (19,292) | |
| Net loss attributable to parent: | (30,881) | (37,340) | (41,301) | (20,699) | (16,757) | (19,292) | ||
| Other undisclosed net loss available to common stockholders, basic | (78) | (8,659) | ||||||
| Net loss available to common stockholders, diluted: | (30,881) | (37,340) | (41,301) | (20,699) | (16,835) | (27,951) | ||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (30,881) | (37,340) | (41,301) | (20,699) | (16,757) | (19,292) | ||
| Comprehensive loss, net of tax, attributable to parent: | (30,881) | (37,340) | (41,301) | (20,699) | (16,757) | (19,292) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.